Show simple item record

dc.contributor.authorSaturno, Gen_US
dc.contributor.authorLopes, Fen_US
dc.contributor.authorNiculescu-Duvaz, Ien_US
dc.contributor.authorNiculescu-Duvaz, Den_US
dc.contributor.authorZambon, Aen_US
dc.contributor.authorDavies, Len_US
dc.contributor.authorJohnson, Len_US
dc.contributor.authorPreece, Nen_US
dc.contributor.authorLee, Ren_US
dc.contributor.authorViros, Aen_US
dc.contributor.authorHolovanchuk, Den_US
dc.contributor.authorPedersen, Men_US
dc.contributor.authorMcLeary, Ren_US
dc.contributor.authorLorigan, Pen_US
dc.contributor.authorDhomen, Nen_US
dc.contributor.authorFisher, Cen_US
dc.contributor.authorBanerji, Uen_US
dc.contributor.authorDean, Een_US
dc.contributor.authorKrebs, MGen_US
dc.contributor.authorGore, Men_US
dc.contributor.authorLarkin, Jen_US
dc.contributor.authorMarais, Ren_US
dc.contributor.authorSpringer, Cen_US
dc.identifier.citationAnnals of oncology : official journal of the European Society for Medical Oncology, 2020en_US
dc.description.abstractBACKGROUND:KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas (PDAC), ∼35% of colorectal cancers (CRC) and ∼20% of non-small-cell lung cancers (NSCLC). There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mutant forms of KRAS are limited, largely because the complexity of downstream signaling and feedback mechanisms mean that targeting individual pathway components is ineffective. DESIGN:The protein kinases RAF and SRC are validated therapeutic targets in KRAS-mutant PDAC, CRC and NSCLC and we show that both must be inhibited to block growth of these cancers. We describe CCT3833, a new drug that inhibits both RAF and SRC which may be effective in KRAS-mutant cancers. RESULTS:We show that CCT3833 inhibits RAF and SRC in KRAS-mutant tumors in vitro and in vivo, and that it inhibits tumor growth at well-tolerated doses in mice. CCT3833 has been evaluated in a Phase I clinical trial (NCT02437227) and we report here that it significantly prolongs progression-free survival of a patient with a G12VKRAS spindle cell sarcoma who did not respond to a multi kinase inhibitor and therefore had limited treatment options. CONCLUSIONS:New drug CCT3833 elicits significant pre-clinical therapeutic efficacy in KRAS-mutant colorectal, lung and pancreatic tumor xenografts, demonstrating a treatment option for several areas of unmet clinical need. Based on these pre-clinical data, and the Phase I clinical unconfirmed response in a patient with KRAS-mutant spindle cell CCT3833 requires further evaluation in patients with other KRAS-mutant cancers.en_US
dc.titleThe paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.en_US
dc.typeJournal Article
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfAnnals of oncology : official journal of the European Society for Medical Oncologyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Pharmacology – Adaptive Therapyen_US
dc.contributor.icrauthorBanerji, Udaien_US

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as